Creabilis Announces Start of Phase IIb Trial of TrkA Kinase Inhibitor CT327 in ... - PR Newswire UK (press release)

Creabilis Announces Start of Phase IIb legal proceeding of TrkA Kinase matter CT327 in ... Pr Newswire UK (press release) Creabilis SA, a continent biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the state of matter IIb global clinical legal proceeding of its lead wares CT327 in patients with psoriasis ... Link To Article